Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s71. https://doi.org/10.25251/skin.6.supp.71